Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

RESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of ...

Health Canada has approved the vaccine, mRESVIA, for the prevention of lower respiratory tract disease in older adults, the company said.

Pfizer and Moderna are hustling to develop an mRNA bird flu vaccine, the same technology used in the companies' respective COVID-19 vaccines.

Cambridge: Moderna, Inc. has announced Health Canada has approved mRESVIA (Respiratory Syncytial Virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease ...

Health Canada approves Moderna’s RSV vaccine, mRESVIA for adults aged 60 years and older: Cambridge, Massachusetts Monday, November 11, 2024, 12:00 Hrs [IST] Moderna, Inc., a le ...

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA ...

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective dropped by research analysts at Barclays from $125.00 to $111 ...